Evidence map›Paper›PMID 39924236›Full record

ArticleInternal medicine (Tokyo, Japan)2025

Pseudo-hyperprogression of Malignant Pleural Mesothelioma Treated with Nivolumab.

Masaaki Yanai, Tomohiro Sakamoto, Takafumi Nonaka, Tatsuya Nakada, Shuichi Matsuoka, Shiro Moriyama, Natsumi Yamamoto, Yasuhiko Teruya, Yoshihiro Funaki, Tomoya Harada and 4 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Masaaki YanaiDivision of Respiratory Medicine and Rheumatology, Tottori University Hospital, Japan.
Tomohiro SakamotoDivision of Respiratory Medicine and Rheumatology, Tottori University Hospital, Japan.
Takafumi NonakaDivision of Respiratory Medicine and Rheumatology, Tottori University Hospital, Japan.
Tatsuya NakadaDivision of Respiratory Medicine and Rheumatology, Tottori University Hospital, Japan.
Shuichi MatsuokaDivision of Respiratory Medicine and Rheumatology, Tottori University Hospital, Japan.
Shiro MoriyamaDivision of Respiratory Medicine and Rheumatology, Tottori University Hospital, Japan.
Natsumi YamamotoDivision of Respiratory Medicine and Rheumatology, Tottori University Hospital, Japan.
Yasuhiko TeruyaDivision of Respiratory Medicine and Rheumatology, Tottori University Hospital, Japan.
Yoshihiro FunakiDivision of Respiratory Medicine and Rheumatology, Tottori University Hospital, Japan.
Tomoya HaradaDivision of Respiratory Medicine and Rheumatology, Tottori University Hospital, Japan.
Naoki KinoshitaDivision of Respiratory Medicine and Rheumatology, Tottori University Hospital, Japan.
Kosuke YamaguchiDivision of Respiratory Medicine and Rheumatology, Tottori University Hospital, Japan.
Masahiro KodaniDivision of Respiratory Medicine and Rheumatology, Tottori University Hospital, Japan.
Akira YamasakiDivision of Respiratory Medicine and Rheumatology, Tottori University Hospital, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Currently, immune checkpoint inhibitors (ICIs) are the standard treatment for malignant pleural mesothelioma (MPM). The characteristic responses to ICI treatment include pseudoprogression (PP) and hyperprogressive disease (HPD), which require attention. Reports on PP of MPM are rare. We herein report a 59-year-old woman with MPM whose pleural lesions rapidly increased in size after initiating nivolumab treatment. This was initially judged as HPD but was subsequently diagnosed as PP owing to a marked reduction in tumor size. This case highlights the importance and difficulty of differentiating between PP and true progression, including HPD, during treatment of MPM with ICIs.

Indexed as

Antineoplastic Agents, ImmunologicalImmune Checkpoint InhibitorsLung NeoplasmsMesothelioma, MalignantNivolumabPleural NeoplasmsDisease ProgressionFemaleHumansMiddle AgedAntineoplastic Agents, ImmunologicalImmune Checkpoint InhibitorsNivolumabhyperprogressive diseaseimmune checkpoint inhibitorsmalignant pleural mesotheliomapseudoprogression

Identifiers

PMID39924236
PMCPMC12393948

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.